Soares Anaïs, Alexandre Kévin, Etienne Manuel
GRAM 2.0, EA 2656, Normandie University, UNIROUEN, Rouen, France.
Infectious Diseases Department, Rouen University Hospital, Rouen, France.
Front Microbiol. 2020 Aug 27;11:2057. doi: 10.3389/fmicb.2020.02057. eCollection 2020.
biofilm-related infections are difficult to treat with antibiotics. Along the different layers of the biofilm, the population is heterogeneous, exhibiting an extreme ability to adapt his metabolic activity to the local microenvironment. At the deepest layers of the biofilm is a subset of dormant cells, called persister cells. Though antimicrobial failure might be multifactorial, it is now demonstrated that these persister cells, genetically identical to a fully susceptible strain, but phenotypically divergent, are highly tolerant to antibiotics, and contribute to antimicrobial failure. By eradicating susceptible, metabolically active cells, antibiotics bring out pre-existing persister cells. The biofilm mode of growth creates microenvironment conditions that activate stringent response mechanisms, SOS response and toxin-antitoxin systems that render the bacterial population highly tolerant to antibiotics. Using diverse, not standardized, models of biofilm infection, a large panel of antibiotic regimen has been evaluated. They demonstrated that biofilm growth had an unequal impact of antibiotic activity, colistin and meropenem being the less impacted antibiotics. Different combination and sequential antimicrobial therapies were also evaluated, and could be partially efficient, but none succeeded in eradicating persister cells, so that non-antibiotic alternative strategies are currently under development. This article reviews the molecular mechanisms involved in antibiotic tolerance and persistence in biofilm infections. A review of the antimicrobial regimen evaluated for the treatment of biofilm infection is also presented. While tremendous progress has been made in the understanding of biofilm-related infections, alternative non-antibiotic strategies are now urgently needed.
生物膜相关感染难以用抗生素治疗。在生物膜的不同层次中,菌群是异质的,表现出极强的能力使其代谢活动适应局部微环境。在生物膜的最深处是一群休眠细胞,称为持留菌。虽然抗菌治疗失败可能是多因素导致的,但现在已经证明,这些持留菌与完全敏感菌株基因相同,但表型不同,它们对抗生素具有高度耐受性,并导致抗菌治疗失败。通过清除敏感的、代谢活跃的细胞,抗生素会使预先存在的持留菌显现出来。生物膜生长模式创造了激活严格反应机制、SOS反应和毒素-抗毒素系统的微环境条件,这些系统使细菌群体对抗生素具有高度耐受性。使用多种(而非标准化的)生物膜感染模型,对大量抗生素治疗方案进行了评估。结果表明,生物膜生长对抗生素活性的影响并不相同,黏菌素和美罗培南受影响较小。还评估了不同的联合和序贯抗菌治疗,它们可能有部分疗效,但均未能成功清除持留菌,因此目前正在开发非抗生素替代策略。本文综述了生物膜感染中抗生素耐受性和持留性的分子机制。还介绍了用于治疗生物膜感染的抗菌治疗方案的综述。虽然在理解生物膜相关感染方面已经取得了巨大进展,但现在迫切需要替代的非抗生素策略。